Study of Immunogenicity and Protective Efficacy of Live MDCK-derived Pandemic Influenza Vaccine
<p>Background: The threat of pandemic A/H1N1 influenza is still a matter of considerable public concern. Influenza outbreak in 2009 underlined the importance of rapid production of a sufficient vaccine reserve for pandemic and interpandemic periods. One promising way to allay this concern is d...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Book |
| Published: |
Global Journal of Infectious Diseases and Clinical Research - Peertechz Publications,
2019-06-06.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | <p>Background: The threat of pandemic A/H1N1 influenza is still a matter of considerable public concern. Influenza outbreak in 2009 underlined the importance of rapid production of a sufficient vaccine reserve for pandemic and interpandemic periods. One promising way to allay this concern is development of cell culture-derived live attenuated influenza vaccines (LAIV), because this technology makes it possible to produce a considerable amount of vaccine over a short period of time.</p><p>Objectives: The goal of this work was to study the immunogenic and protective properties of the Vector-Flu vaccine in animal models.</p><p>Methods: We have developed Vector-Flu, a live attenuated vaccine against pandemic influenza, based on the cold-adapted reassortant vaccine strain for LAIV, A/17/California/2009/38(H1N1), and produced in certified MDCK cells. The immunogenicity and protective efficacy of Vector-Flu vaccine were studied in ferrets and mice.</p><p>Results: A double immunization with the live MDCK-derived Vector-Flu influenza vaccine induced a high level of neutralizing antibodies in ferret serum both to the pandemic A/Chita/3/2009(H1N1) influenza virus strain, isolated in Russia, and to the pandemic A/California/7/2009(H1N1) strain. Intranasal immunization of mice induced levels of serum antibodies sufficient to protect them when aerosol-challenged with 100 infectious doses of A/Chita/3/2009(H1N1) strain. </p><p>Conclusion: Theoretical estimates of protective antibody levels necessary for protecting humans from the disease caused by pandemic A/H1N1(2009) influenza virus, and the experimental data from animal models (ferrets and mice), suggest that the Vector-Flu vaccine is able to protect humans after a single immunization.</p> |
|---|---|
| DOI: | 10.17352/2455-5363.000023 |